Article detail · 2013
title Colistin ivs/i . the combination of colistin and rifampicin for the treatment of carbapenem-resistant iAcinetobacter baumannii/i ventilator-associated pneumonia/title
- Year
- 2013
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue EPIDEMIOLOGY AND INFECTION
- Catalog match (ISSN) Epidemiology and Infection
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
English (OpenAlex)
The aim of this study was to compare the responses of colistin treatment alone vs. a combination of colistin and rifampicin in the treatment of ventilator-associated pneumonia (VAP) caused by a carbapenem-resistant A. baumannii strain. Forty-three patients were randomly assigned to one of two treatment groups. Although clinical (P = 0·654), laboratory (P = 0·645), radiological (P = 0·290) and microbiological (P = 0·597) response rates were better in the combination group, these differences were not significant. However, time to microbiological clearance (3·1 ± 0·5 days, P = 0·029) was significantly shorter in the combination group. The VAP-related mortality rates were 63·6% (14/22) and 38·1% (8/21) for the colistin and the combination groups (P = 0·171), respectively. Our results suggest that the combination of colistin with rifampicin may improve clinical and microbiological outcomes of VAP patients infected with A. baumannii.
Topics
- Antibiotic Resistance in Bacteria
- Pneumonia and Respiratory Infections
- Antibiotics Pharmacokinetics and Efficacy
Primary topic Antibiotic Resistance in Bacteria